Clarametyx Biosciences has developed biologic therapies and vaccines for biofilm-related bacterial infections affecting the respiratory tracts. The company has developed its lead product CMTX-001, an immune-enabling antibody therapy, to treat hospital-acquired pneumonia (preclinical development stage). It is also developing therapies for cystic fibrosis, sinusitis, and post-tympanostomy tube otorrhea.
← All startups
Clarametyx
Series AClarametyx Biosciences has developed biologic therapies and vaccines for biofilm-related bacterial infections affecting the respiratory tracts. The company has developed its lead product CMTX-001, an immune-enabling antibody therapy, to treat hospital-acquired pneumonia (preclinical development stage). It is also developing therapies for cystic fibrosis, sinusitis, and post-tympanostomy tube otorrhea.
About
Institutional investors
CARB-XOhio Innovation FundNationwide Children's HospitalRev1 VenturesJobsOhioC Bio Investors1776 VenturesNIHKineticosHHS
Latest coverage
📰 Latest funding news — recent raises and deal signals across the ecosystem.
Investor directory
🗂️ See who's investing in Life Sciences — full fund directory with check size and geography.